Survodutide — Dose Evidence | Peptides Community

Reference only — not a dosing recommendation.

Not established

No approved labeled regimen

No established or recommended human dose.

Not applicable — no marketing authorization was identified in the major regulator databases reviewed as of the verification date.

Studied in trials

Studied regimens (not recommendations)

Studied in trials — not a recommended dose

No established or recommended human dose.
Phase 2 trials used once-weekly subcutaneous administration with forced dose escalation over multiple weeks. Highest studied weekly doses: 4.8 mg (obesity Phase 2), 6.0 mg (MASH Phase 2). SYNCHRONIZE-1 studied doses adjusted up to 3.6 mg or 6.0 mg once weekly. These trial exposures are descriptive, not recommended regimens.

Not established

What is not established

No safe or effective dose has been confirmed by regulatory review. Optimal dose-escalation protocol, maximum tolerated dose, durability of effect beyond 76 weeks, and long-term safety are not established.

Survodutide —— 专论剂量与给药证据章节